Kyorin Pharmaceutical revised its current-year ordinary profit forecast downward to a loss. Although it was profitable on a cumulative second-quarter basis, it is expected to fall into a loss for the full year.
Kyorin Pharmaceutical announced its results after the close of trading on 9 November. Consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2027 was ¥680 million, down 56.4% year on year, while the company finished the period in the black despite its previous forecast for a loss. It also revised its full-year earnings forecast downward, from a projected profit to a ¥4.6 billion loss.
The announced reasons for revising the full-year earnings forecast included the recognition of an upfront payment associated with the licensing agreement for EB05, a candidate treatment for ARDS, and the greater certainty of an agreement for in-licensed products based on progress in discussions with the counterparty. Special losses related to the transfer of rights during the interim period also had an impact.
Compared with the previous forecast, first-half actual results were revenue of ¥57,489 million, operating profit of ¥306 million, ordinary profit of ¥689 million and net loss of ¥1,566 million, representing a return to profitability from the pre-revision forecast. The revised dividend per share is ¥10.
The second-half earnings forecast is for revenue of ¥64,311 million, an operating loss of ¥5,206 million, an ordinary loss of ¥5,289 million and a net loss of ¥3,534 million, indicating a return to a loss outlook.